The Skinny On Induced Infringement And Label Carve-Outs
By EsqSocial Corporation 08/02/21
On January 13, 2021, we originally posted on this topic (click here). This post provides an update to this matter. The Federal Circuit invited GSK to respond to Teva’s en banc petition, and on January 29 respond it did. GSK made clear its position that the Court’s October 2, 2020 opinion reversing the JMOL and remanding for entry of the jury verdict does not spell “doomsday” for section viii carveouts. GSK stated that the “case does not implicate the fate of section viii carve-outs” and...
By: Kilpatrick Townsend & Stockton LLP